Treatment aimed at people who cannot be vaccinated is boost to firm’s coronavirus portfolio
AstraZeneca has received UK regulatory approval for its long-acting Covid-19 antibody treatment Evusheld in a boost to its coronavirus portfolio as the British-Swedish drugmaker targets greater drug development success at its new £1bn research lab in Cambridge.
Aimed at preventing Covid infections in people with poor immune systems who cannot be vaccinated, Evusheld is already approved in the US and other countries, and the US government has ordered 1.7m doses.
